Home › Mga Krisis sa Vaso-Occlusive
Pag-aaral pangklinika para sa Mga Krisis sa Vaso-Occlusive na nagre-recruit sa U.S.
7 pag-aaral para sa Mga Krisis sa Vaso-Occlusive ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
Ayos sa estado
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Nagre-recruitPhase 3
Edad 12 hanggang 100 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06439082Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Nagre-recruitPhase 2
Edad 5 hanggang 20 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07369024Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT07224360Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Nagre-recruitPhase 4
6 Months – 100 Years · Lahat ng kasarian · Na-update Hun 8, 2026 · NCT04657822Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Nagre-recruit
Edad 6 hanggang 25 · Lahat ng kasarian · Na-update May 18, 2026 · NCT03353584Sickle Cell Improvement: Enhancing Care in the Emergency Department
Nagre-recruit
Hanggang edad 18 · Lahat ng kasarian · Na-update Ago 14, 2023 · NCT05373771Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.